ZVSA

News

globenewswire.comZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 13

globenewswire.comZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Updateglobenewswire.comMar 31

Trade ZVSA

About ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

CEO: Stephen C. Glover
IPO Date: Feb 11, 2022

Market Data

Open: $0.1946
High: $0.1946
Low: $0.1611
Volume: 1
Avg Volume: 10.4K
52W High: $1.67
52W Low: $0.11

Valuation

Market Cap: $1.5M
Enterprise Value: $899M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-5.1M
Revenue: $0
Net Income: $-25M
Cash: $102M
Debt: $0

Events

EarningsAug 13